ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Venetoclax Dosing & APOLLO"
Episode Synopsis
Malignant Hematology Updates:
Venetoclax dosing strategies continue to evolve
HMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00640
HMA/Ven + revumenib: https://doi.org/10.1200/JCO-25-00914
Venetoclax + CPX-351: https://doi.org/10.1002/ajh.27723
APOLLO: https://doi.org/10.1200/JCO-25-00535
Iland APOLLO editorial: https://doi.org/10.1200/JCO-25-01496
ctDNA assessment vs. PET in Large B-Cell Lymphoma: https://doi.org/10.1200/JCO-25-01534
Venetoclax dosing strategies continue to evolve
HMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00640
HMA/Ven + revumenib: https://doi.org/10.1200/JCO-25-00914
Venetoclax + CPX-351: https://doi.org/10.1002/ajh.27723
APOLLO: https://doi.org/10.1200/JCO-25-00535
Iland APOLLO editorial: https://doi.org/10.1200/JCO-25-01496
ctDNA assessment vs. PET in Large B-Cell Lymphoma: https://doi.org/10.1200/JCO-25-01534
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust